PharmaDrug Engages Octagon Media and Affiliated Wall Street Reporter for Investor Marketing Campaign Post published:January 20, 2022 Post category:Press Release
BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001 Post published:January 20, 2022 Post category:Press Release
Psychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II Post published:January 20, 2022 Post category:Press Release
Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial Post published:January 19, 2022 Post category:Press Release
Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study Post published:January 19, 2022 Post category:Press Release
Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression Post published:January 19, 2022 Post category:Press Release
Red Light Holland to Collaborate with Advocacy Group, Psychedelic Medicine Alliance Washington to Promote Proposed Psilocybin Legalization Bill in Washington State Post published:January 18, 2022 Post category:Press Release
Optimi Health Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations for Provisional Patent Post published:January 18, 2022 Post category:Press Release
Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today Post published:January 18, 2022 Post category:Press Release